Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase II Study
BMS-986278, a potential first-in-class oral lysophosphatidic acid receptor 1 (LPA1) antagonist, was studied in patients with progressive pulmonary fibrosis (PPF) in a Phase II research, according to Bristol Myers Squibb. The study found that taking 60 mg of BMS-986278 twice a day for 26 weeks reduced the rate of decline in percent projected forced vital capacity (ppFVC) by 69% compared to placebo (overall, 38% of patients in the trial had baseline antifibrotic medication). These findings will be presented at the Eur...
